Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 18:7:100192.
doi: 10.1016/j.crphar.2024.100192. eCollection 2024.

The relationship between gender and pharmacology

Samer Younes  1
Affiliations

The relationship between gender and pharmacology

Samer Younes. Curr Res Pharmacol Drug Discov. .

Abstract

The part of sexuality in pharmacology research was not acknowledged, and it was not thought-out to be a determinant that could impact strength and disease. For decades research has mainly contained male, women and animals, leading to a lack of news about syndromes in females. Still, it is critical to guarantee equal likeness so that determine the security, influence, and resistance of healing agents for all individuals. The underrepresentation of female models in preclinical studies over various decades has surpassed to disparities in the understanding, disease, and treatment of ailments 'tween genders. The closeness of sexuality bias has happened recognized as a contributing determinant to the restricted interpretation and replicability of preclinical research. Many demands operation have stressed the significance of including sexuality as a organic changeable, and this view is acquire growing support. Regardless of important progress in incorporating more female models into preclinical studies, differences prevail contemporary. The current review focuses on the part of sexuality and common in biomedical research and, therefore, their potential function in pharmacology and analyze the potential risks guide.

Keywords: Gender; Pharmacology; Sex.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
PRISMA checklist (Flowchart of the study selection process).
Fig. 2
Fig. 2
Phyisiological difference in PK, PD of drugs.
Fig. 3
Fig. 3
Sex differences im drug processing.
Fig. 4
Fig. 4
Age, sex, drug trials in women.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Anderson G.D. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 2005;44:989–1008. - PubMed
    1. Anderson G.D. Gender differences in pharmacological response. Int. Rev. Neurobiol. 2008;83:1–10. - PubMed
    1. Anker J.J., Carroll M.E. vol. 8. Springer; Berlin/Heidelberg, Germany: 2011. Females are more vulnerable to drug abuse than males: evidence from preclinical studies and the role of ovarian hormones; pp. 73–96. (Biological Basis of Sex Differences in Psychopharmacology; Current Topics in Behavioral Neurosciences). - PubMed
    1. Anthony M., Berg M.J. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II. J. Womens Health Gend. Based Med. 2002;11:617–629. - PubMed
    1. Arnold A.P. A general theory of sexual differentiation. J. Neurosci. Res. 2017;95:291–300. - PMC - PubMed

LinkOut - more resources